Improvement of overall survival in advanced stage mantle cell lymphoma.

  title={Improvement of overall survival in advanced stage mantle cell lymphoma.},
  author={Annina Herrmann and Eva Hoster and Thomas Zwingers and Günter Brittinger and Marianne Engelhard and Peter Meusers and Marcel Reiser and Roswitha Forstpointner and Bernd Metzner and Norma Peter and Bernhard W{\"o}rmann and Lorenz H. Tr{\"u}mper and Michael Pfreundschuh and Hermann Einsele and Wolfgang Hiddemann and Michael Unterhalt and Martin Dreyling},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={27 4},
  • Annina Herrmann, E. Hoster, M. Dreyling
  • Published 1 February 2009
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis. To explore a potential progress in outcome a historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and the German Low Grade Lymphoma Study Group (GLSG; 1996 to 2004). PATIENTS AND METHODS All patients with the histologically confirmed diagnosis of advanced-stage nonblastoid MCL were eligible. To minimize the potential heterogeneity of… 

Figures and Tables from this paper

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report
Limited-state MCL showed indolent clinical and low-risk prognostic features and Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
By a population-based approach, this work was able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice, and rituximab and autologous stem cell transplant were independently associated with improved OS in multivariate analysis.
How I treat mantle cell lymphoma.
The prognosis of patients with mantle cell lymphoma (median overall survival, 3-5 years) is poorest among B-cell lymphoma patients, even though a prospectively difficult to identify subgroup can survive for years with little or no treatment.
Predictors of Indolent Versus Aggressive Disease Behavior for Patients With Newly Diagnosed Mantle Cell Lymphoma
This review summarizes the currently available data regarding identification of indolent compared with aggressive disease, the role of ASCT in first remission, and the appropriate scenarios in which to use maintenance therapies.
Mantle cell lymphoma epidemiology: a population-based study in France
It is confirmed that MCL remains an aggressive NHL with a median overall survival less than 4 years and demonstrates that the use of rituximab in first-line treatment has modified overall survival duration.
Mantle cell lymphoma.
It is critical that patients with a more indolent disease have been reported in whom the initiation of therapy can be delayed without any consequence for the survival, since the optimal approach to the management of MCL is still evolving.
How I treat How I treat mantle cell lymphoma
The prognosis of patients with mantle cell lymphoma is poorest among B-cell lymphoma patients, even though a prospectively difficult to identify subgroup can survive for years with little or no treatment, and the possibility of treating patients based on prognostic factors needs to be investigated prospectively.
Clinical profile, treatment, and outcomes of patients with mantle cell lymphoma treated in a tertiary care center in South India
Most patients presented with extranodal disease, advanced stage, and high IPI, and although rituximab has improved survival, intensive chemotherapy would be required to improve survival.
Diagnosis and treatment of mantle cell lymphoma.
The use of effective immunochemotherapy regimens in first-line therapy, advances in stem cell transplantation, and the development of more active salvage therapy regimens have improved the outcome.


Patterns of survival in mantle cell lymphoma.
A survival advantage with anthracycline-containing regimens in some patients with MCL is suggested, however, this benefit was evident only for the patients with favourable International Index prognostic scores who may already have a better prognosis.
Improved survival of follicular lymphoma patients in the United States.
The survival of patients with FL in the United States has improved over the last 25 years, and the survival improvement may be a result of the sequential application of effective therapies and improved supportive care.
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
In both subtypes, patients with less than two residual lymphoma manifestations in remission experienced a relatively good prognosis with an estimated 5-year survival of greater than 60% for MCL and greater than 75% for FCL.
A predictive model for aggressive non-Hodgkin's lymphoma.
The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.
In patients with indolent or mantle cell lymphoma, R-chemo is superior to chemotherapy alone with respect to overall survival.
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
  • O. HowardJ. Gribben M. Shipp
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
Favorable clinical and molecular response rates associated with rituximab and CHOP chemotherapy do not translate into prolonged PFS in MCL, prompting additional consideration of antibody-based in vivo purging in subsequent clinical trials.
Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
Within a multicentre observation study on non‐Hodgkin lymphomas (NHL) diagnosed according to the Kiel classification advanced stages III and IV of centrocytic (CC) lymphoma exhibited the worst
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL, and longer follow-up is needed to determine the effect on OS.